共 223 条
[1]
Goetz MP(2018)Clinical Pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and Tamoxifen therapy Clin Pharmacol Ther 103 770-777
[2]
Sangkuhl K(2011)Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet. 378 771-784
[3]
Guchelaar H-J(1977)A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity J Endocrinol 75 305-316
[4]
Schwab M(2011)Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes Clin Pharmacol Ther 89 718-725
[5]
Province M(2004)Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6 J Pharmacol Exp Ther 310 1062-1075
[6]
Whirl-Carrillo M(2011)Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma Clin Pharmacol Ther 89 708-717
[7]
Jordan VC(2013)PharmGKB summary: tamoxifen pathway, pharmacokinetics Pharmacogenet Genomics 23 643-647
[8]
Collins MM(2005)Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 9312-9318
[9]
Rowsby L(2007)Breast Cancer treatment outcome with adjuvant Tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes J Clin Oncol 25 5187-5193
[10]
Prestwich G(2009)Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen JAMA. 302 1429-1436